{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:28:58Z","timestamp":1772605738198,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ygyno.2016.05.017","type":"journal-article","created":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T00:06:53Z","timestamp":1464307613000},"page":"231-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study"],"prefix":"10.1016","volume":"142","clinical-trial-number":[{"clinical-trial-number":"nct01239732","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01462890","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01802749","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"M.","family":"Petrillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Amadio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Paris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.G.","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ferandina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2016.05.017_bb0005","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0010","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0015","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0020","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/IGC.0b013e31829f17c9","article-title":"Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer","volume":"23","author":"Rauh-Hain","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.05.017_bb0025","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.5505","article-title":"Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin\u2013paclitaxel (CP)\u00b1bevacizumab (BEV) for epithelial ovarian cancer (EOC)","volume":"33","author":"Birrer","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"5s","key":"10.1016\/j.ygyno.2016.05.017_bb0030","article-title":"Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab","volume":"32","author":"Gourley","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ygyno.2013.08.005","article-title":"Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience","volume":"131","author":"Fagotti","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0040","doi-asserted-by":"crossref","first-page":"462.e1","DOI":"10.1016\/j.ajog.2013.07.016","article-title":"A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer","volume":"209","author":"Fagotti","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2013.06.020","article-title":"Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors","volume":"131","author":"Petrillo","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0050","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1245\/s10434-014-4011-0","article-title":"Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer","volume":"22","author":"Fanfani","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0055","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000159266","article-title":"A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET\/CT and staging laparoscopy","volume":"75","author":"Fagotti","year":"2008","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2016.05.017_bb0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.05.017_bb0065","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"Am. J. Stat. Assoc."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0070","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0085","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0090","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","article-title":"Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer","volume":"32","author":"Stockler","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0095","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0100","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2014.58.3690","article-title":"Time for a level playing field: inequalities in regulatory\/approval processes\u2014the example of bevacizumab in epithelial ovarian cancer","volume":"33","author":"Hoskins","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 3","key":"10.1016\/j.ygyno.2016.05.017_bb0105","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1245\/s10434-015-4651-8","article-title":"Neoadjuvant chemotherapy followed by maintenance therapy with or without bevacizumab in unresectable high-grade serous ovarian cancer: a case-control study","volume":"22","author":"Petrillo","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.017_bb0110","series-title":"Role of macrophages in adaptive resistance to anti-vegf therapy","author":"Dalton","year":"2014"},{"key":"10.1016\/j.ygyno.2016.05.017_bb0115","first-page":"123","article-title":"Tumor-associated macrophages as an emerging target against tumors: creating a new path from bench to bedside","volume":"2015","author":"Jinushi","year":"1855","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ygyno.2016.05.017_bb0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ygyno.2015.12.033","article-title":"Prediction of anti-angiogenesis escape","volume":"141","author":"Mitamura","year":"2016","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816307417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816307417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T05:04:52Z","timestamp":1718600692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825816307417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0090825816307417"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.017","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}